1. Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers. (March 2021) Authors: Benkova, Katerina; Mihalyova, Jana; Hajek, Roman; Jelinek, Tomas Journal: Blood reviews Issue: Volume 46(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Single‐agent venetoclax induces MRD‐negative response in relapsed primary plasma cell leukemia with t(11;14). Issue 1 (25th November 2018) Authors: Jelinek, Tomas; Mihalyova, Jana; Kascak, Michal; Duras, Juraj; Popkova, Tereza; Benkova, Katerina; Richterova, Petra; Plonkova, Hana; Zuchnicka, Jana; Broskevicova, Lucie; Huvarova, Lucie; Cerna, Lucie; Growkova, Katerina; Simicek, Michal; Havel, Martin; Gumulec, Jaromir; Navratil, Milan; Koriste... Journal: American journal of hematology Issue: Volume 94:Issue 1(2019:Jan.) Page Start: E35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Venetoclax plus bortezomib and dexamethasone in heavily pretreated end‐stage myeloma patients without t(11;14): A real‐world cohort. Issue 3 (23rd April 2020) Authors: Jelinek, Tomas; Popkova, Tereza; Duras, Juraj; Mihalyova, Jana; Kascak, Michal; Benkova, Katerina; Plonkova, Hana; Cerna, Lucie; Koristek, Zdenek; Simicek, Michal; Hajek, Roman Journal: Hematological oncology Issue: Volume 38:Issue 3(2020) Page Start: 412 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗